SEARCH · Search PubMed

Results for “SALICYLAMIDE”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

SourceResearch connectionFrom yearThrough year

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,261 records · Page 70Linked to original sources

PubMed2001

A dopamine partial agonist and antagonist block amphetamine self-administration in a progressive ratio schedule.

A recently characterized class of compounds, dopamine partial agonists, have been suggested as potential therapeutic candidates for pharmacological intervention in psychostimulant addiction. These drugs bind to dopamine receptors with high affinity and low intrinsic activity and are thought to behave as functional antagonists in conditions of high dopaminergic tone, and as agonists in conditions of low receptor occupancy by dopamine. The aim of the present study was to characterize the effects of terguride, a partial dopamine agonist at the D2 receptor subtype, on intravenous self-administration of amphetamine in a progressive ratio schedule and to compare it with the effects produced by the dopamine D2 antagonist eticlopride and the dopamine D2 full agonist quinpirole. Terguride at the doses of 0.2 and 0.4 mg/kg i.p. significantly decreased the maximum number of responses delivered for a single injection of amphetamine ("breaking point"), an effect similar to that produced by the antagonist eticlopride (0.01-0.1 mg/kg s.c.). In contrast, administration of quinpirole (0.1-1 mg/kg s.c.) did not significantly modify the breaking point for amphetamine responding. Also, terguride dose-dependently increased responding for amphetamine self-administration on a continuous reinforcement schedule. These data further confirm the effects of terguride on psychostimulant self-administration and indicate that under these conditions partial dopamine agonists act as functional dopamine receptor antagonists.

Amphetamine↗

PubMedDate not supplied

Low-level lead exposure modulates effects of quinpirole and eticlopride on response rates in a fixed-interval schedule.

Exposure to low levels of lead (Pb) results in a wide range of behavioral changes. These behavioral deficits of lead are modified by duration of exposure, level of exposure, and stage of exposure. The mesoaccumbens dopamine (DA) system appears to be critically involved in these alterations; however, the precise mechanisms are not completely understood. This study investigated the effects of systemic administrations of the dopamine D(2)-like receptor agonist, quinpirole, and antagonist, eticlopride, on response rates of postweaning lead-exposed rats in a fixed-interval 1-minute (FI-1) schedule. Postweaning exposure to 50 ppm lead (lead acetate) resulted in increased response rates. The dopamine D(2)-like agonist, quinpirole (0.05, 1.0, 3.0 mg/kg), reversed the effects of lead by reducing the response rates. However the antagonist, eticlopride (0.01 and 0.05), did not produce any marked modulation of the response rates of the lead group. Rather, systemic injections of eticlopride attenuated the response rates of control rats. The effects suggest that lead-induced alterations in FI responding are modulated by dopamine D(2)-like mechanisms. Thus, postweaning, subchronic exposure to lead resulted in enhanced sensitivity to quinpirole administration and reduced sensitivity to eticlopride. These observations are consistent with attenuated dopaminergic activity.

Animals↗

PubMed2002

Locomotor stimulant effects of nornicotine: role of dopamine.

Nornicotine (NORNIC) is a tobacco alkaloid and behaviorally active nicotine metabolite in vivo. Previous behavioral research has shown that NORNIC has locomotor stimulant and reinforcing effects in rats similar to that of nicotine. Results from the current study showed that a bilateral lesion of the nucleus accumbens decreased the locomotor stimulant effect of NORNIC across repeated injections. Pretreatment with the dopamine (DA) D1 receptor antagonist SCH23390 did not block the locomotor stimulant effect of NORNIC or the initiation of sensitization following repeated NORNIC administration. The D2 receptor antagonist eticlopride, however, blocked both the stimulant effect and the initiation of sensitization following repeated NORNIC. Additionally, NORNIC was found to increase synthesis and metabolism of DA, with a greater effect in the mesolimbic pathway compared to the nigrostriatal pathway. Taken together, these results suggest that expression of NORNIC-induced locomotor activity is dependent upon ascending dopaminergic mesolimbic projections, providing additional evidence that NORNIC plays a contributory role in tobacco dependence.

3,4-Dihydroxyphenylacetic Acid↗

PubMed2003

The modulatory actions of dopamine D2/3 agonists and antagonists on the locomotor-activating effects of morphine and caffeine in mice.

Morphine produces robust increases in locomotor activity in mice. Recent data indicate that dopamine (DA) D2/3 agonists attenuate the discriminative stimulus and antinociceptive effects of mu opioid agonists such as morphine. The present study was designed to determine the extent to which D2/3 receptor activation and blockade can modulate morphine-induced locomotion using a novel cumulative dosing procedure in Swiss-Webster mice. The results indicate that morphine-induced locomotion is nonsignificantly attenuated by the D2/3 agonists quinelorane and quinpirole, whereas the D2/3 antagonists eticlopride and nafadotride, as well as the partial D2/3 agonist BP897, significantly reduced morphine-induced locomotion. To determine the specificity of this modulation, these agonists and antagonists were examined in combination with caffeine, a drug that also indirectly alters DAergic activity. Unlike the effects on morphine, caffeine-induced locomotion was unaltered by eticlopride, nafadotride and BP897, but was attenuated by quinelorane and quinpirole. These results indicate that modulation of D2/3 receptors can, in turn, alter the locomotor-activating effects of morphine.

Animals↗

PubMed1997

Different effects of dopamine antagonists on spontaneous and NMDA-induced motor activity in mice.

The spontaneous motor activity of mice exposed to a new environment is characterized by an initial hyperactivity (exploratory period) followed by low levels of motor activity (habituation period). High doses of the dopamine D1 receptor antagonist SCH 23390 (1 mg/kg SC) and the dopamine D2 receptor antagonist raclopride (1 mg/kg SC) partially decreased motor activity during the exploratory period and did not modify motor activity during the habituation period or after reserpinization (5 mg/kg SC 20 h before motor activity recording). The systemic administration of a subconvulsant dose of N-methyl-D-aspartate (NMDA) (75 mg/kg IP) decreased motor activity during the exploratory period and increased motor activity during the habituation period. Both SCH 23390 and raclopride partially counteracted the NMDA-induced motor activation. Neither SCH 23390 nor raclopride counteracted the NMDA-induced motor activation in reserpinized mice. On the contrary, raclopride was found to potentiate the NMDA-induced motor activation in reserpinized animals. The present results suggest the existence of dopamine-dependent and dopamine-independent mechanisms involved in the motor activating effects of NMDA.

Animals↗

PubMed1997

A role for D2, but not D1, dopamine receptors in the response-reinstating effects of food reinforcement.

Although the reinforcing properties of food are reduced in the presence of dopamine antagonist drugs, controversy exists about the relative roles of D1 vs D2 receptor subtypes in the actions of these drugs. The current experiment compared the effects of raclopride (a selective D2 receptor antagonist) and SCH 39166 (a selective D1 receptor antagonist) in the response-reinstating effects of food reinforcement. Hungry rats were trained to run a straight-alley for food reinforcement during single daily trials. The operant was then extinguished during consecutive daily non-reinforced trials. Subjects were then injected with one of four doses of raclopride (0.0, 1.0, 0.5, and 0.25 mg/kg, i.p.) or SCH 39166 (0.0, 1.0, 0.5, and 0.1 mg/kg i.p.) 30 min prior to a single reinforced treatment trial. Twenty-four h later, a test trial was conducted in an unbaited runway. The single reinforced trial in the midst of extinction was observed to reinstate operant runway performance. Raclopride, but not SCH 39166, dose-dependently attenuated this reinstatement. Motor control groups ruled out the possibility that these results were due to differential residual motor effects of the drugs. Results suggest that D2, but not D1, dopamine receptors, are involved in the response-reinstating properties of food reinforcement.

Animals↗

PubMed1997

Bidirectional effects of dopamine D2 receptor antagonists on responding for a conditioned reinforcer.

In general, the administration of dopamine (DA) antagonists has been shown to result in the attenuation of reward processes. Recently, however, it has been suggested that low doses of DA antagonists can enhance the incentive value of a primary reinforcer. The present study examined the effect of DA receptor antagonists on responding for a conditioned stimulus (CS) and compared their effects to that produced by d-amphetamine. For 12 days, food-deprived rats were trained to associate a CS with a food reward. In the test phase, the CS was presented following a response on one of two levers (CR), whereas responding on the other lever (NCR) had no consequence. Low doses of d-amphetamine (0.5 mg/kg), sulpiride (4 mg/kg), pimozide (0.025 mg/kg), and raclopride (0.05 mg/kg) selectively enhanced responding on CR. A low dose of haloperidol (0.01 mg/kg) led to a nonspecific increase in lever responding. Treatment with larger doses of these compounds as well as with the D1 antagonist SCH23390 attenuated responding on CR. Both CR and NCR responding were reduced following administration of higher doses of d-amphetamine. Results indicate that responding for a conditioned reinforcer is potentiated following administration of low doses of D2 receptor antagonists, suggesting that D2 receptor blockade can facilitate incentive motivation.

Amphetamine↗

PubMed1997

Use of positron emission tomography to study the dynamics of psychostimulant-induced dopamine release.

Microdialysis studies have shown that psychostimulants act through a common neurochemical mechanism of elevating synaptic dopamine content in the mesocorticolimbic dopaminergic system. However, little information is available regarding the dynamics of the interaction between the elevated synaptic dopamine levels induced by a psychostimulant and postsynaptic dopamine receptors. The goal of the current investigation was to determine if positron emission tomography (PET) studies using the dopamine D2-selective radioligand [18F]4'-fluoroclebopride ([18F]FCP) could be used to measure synaptic dopamine levels. Rhesus monkeys were used because our previous studies revealed that [18F]FCP has a low test/retest variability in this species. Under control conditions, [18F]FCP had a high uptake and slow rate of washout from the basal ganglia, a region of brain that expresses a high density of D2 receptors, reaching kinetic equilibrium at approximately 40 min. Challenge studies, each separated by at least 1 month, were conducted by administering an intravenous dose of (-)cocaine, d-amphetamine, methylphenidate, or d-methamphetamine (1.0 mg/kg) at 40 min post-IV injection of a no-carrier-added dose of [18F]FCP. In each case, the psychostimulant caused an increase in the rate of washout of [18F]FCP from the basal ganglia. Methamphetamine and amphetamine had more pronounced effects on the washout kinetics of [18F]FCP relative to cocaine and methylphenidate, a result that is consistent with the ability of each drug to elevate synaptic dopamine levels. Our results indicate that challenge studies with [18F]FCP may be a useful technique for studying the dynamics of the interaction between psychostimulant-induced increases in synaptic dopamine and postsynaptic D2 receptors.

Animals↗

PubMed1998

A comparison of the effects of risperidone, raclopride, and ritanserin on intravenous self-administration of d-amphetamine.

These experiments were conducted to examine the effects of simultaneous blockade of dopamine D2 and 5-hydroxytryptamine2 (5-HT) receptor function on responding for intravenous infusions of d-amphetamine. Rats were trained to self-administer d-amphetamine intravenously according to a progressive ratio schedule of reinforcement, in which response requirements increased for successive infusions until responding extinguished. In the first experiment it was shown that increases in the unit infusion dose of d-amphetamine resulted in an increase in the number of amphetamine infusions earned. Thus, the strength of responding for d-amphetamine was linked to the dose of drug received. The mixed D2 and 5-HT2 receptor antagonist risperidone (0.1, 0.2, and 0.4 mg/kg) reduced responding for d-amphetamine (60 microg/kg infusion). The selective D2 antagonist raclopride (0.1, 0.2, and 0.4 mg/kg) also reduced responding for d-amphetamine. In contrast, the selective 5-HT2 antagonist ritanserin (0.63, 1.25, and 2.5 mg/kg) failed to alter amphetamine self-administration. Combined injections of raclopride (0.05 or 0.1 mg/kg) and ritanserin (2.5 mg/kg) were no more effective than injections of raclopride alone in reducing responding for d-amphetamine. Overall, these results suggest that 5-HT2 receptor blockade plays a negligible role in the rewarding effects of d-amphetamine measured by intravenous self-administration, and does not contribute to the suppressant effects of risperidone on this behavior.

Animals↗

PubMed1998

Sex differences in escape-avoidance response in mice after acute administration of raclopride, clozapine, and SCH 23390.

Sex differences in the effects of haloperidol in the escape-avoidance response in mice have previously been found in various studies carried out in our laboratory. Males were more affected than females by the disruptive effects of this neuroleptic. The work described herein extended the study of these sex differences to raclopride, clozapine, and SCH 23390, using several doses of each drug in acute administration. The results showed dose-dependent sex differences in the deteriorating effects of these dopamine antagonists in the escape-avoidance response. Male mice were more affected by the inhibitory effects of these drugs, showing fewer escape responses and more nonresponses than females. Sex differences were found with all three of the dopamine antagonists studied, indicating, therefore, that these differences do not depend on a unique type of dopaminergic receptor. The results obtained in motor activity, measured by the number of crossings during the adaptation period and the intertrial intervals, suggest that the motor effects are not the origin of these differences. It is concluded that, besides haloperidol, other dopamine antagonists also show sex differences in their behavioral effects in escape-avoidance response in mice, with males being more affected than females by the inhibitory action of these drugs.

Animals↗

PubMed1998

Effects of dopamine antagonists and accumbens dopamine depletions on time-constrained progressive-ratio performance.

Four experiments were conducted to determine the effects of dopamine (DA) antagonists and DA depletions on progressive-ratio responding for food reinforcement. On this schedule, ratio requirement increased by one response after each reinforcer was obtained, and rats were tested in 30-min sessions. Response rates and highest ratio completed were reduced in a dose-related manner by systemic injections of the D1 antagonist SCH 23390, and also by the D2 antagonists haloperidol and raclopride. Drug-treated rats also showed reductions in time to complete the last ratio, demonstrating that they had stopped responding before the end of the session. DA depletions produced by injections of 6-OHDA directly into the nucleus accumbens substantially decreased both the number of responses and the highest ratio completed. The deficits in response number and highest ratio completed induced by DA depletions persisted through the first 3 weeks of postsurgical testing, with some recovery by the fourth week. However, the deficits resulting from dopamine depletions were largely a manifestation of a decrease in response rate; although time to complete the last ratio was significantly reduced by dopamine depletions in the first few days of testing, rats recovered on this measure by the fifth day after surgery. Although previous work has shown that performance on several schedules (e.g., continuous, low value ratios, variable interval) is relatively unaffected by accumbens DA depletions, the present data demonstrate that such depletions do produce a substantial and persistent impairment of progressive ratio response output. Rats with accumbens DA depletions appear to have deficits in maintaining the high work output necessary for responding at large ratio values. The relative sparing of responding on some simple schedules, together with the present progressive ratio results, suggest that rats with accumbens DA depletions remain directed toward the acquisition and consumption of food, but they show deficits in work output for food.

Animals↗

PubMed1999

Effects of SCH23390 and raclopride on anxiety-like behavior in rats tested in the black-white box.

Dopamine (DA) systems are activated by stress, and this response has as a corollary the induction of stress-related behaviors such as anxiety. In mice, D2 receptor blockade produces an apparent anxiogenic effect, although locomotor impairments might have been present. We investigated the effects of D1 and D2 antagonists on a variety of anxiety-like behaviors induced by the black-white box in rats and carefully screened for any locomotor deficits. Adult male Lister hooded rats were injected with either the D1 antagonist SCH23390 (0. 0.1. or 0.25 mg/kg i.p.) or the D2 antagonist raclopride (0, 0.05, or 0.10 mg/kg i.p.) 20 min prior to being placed into the white chamber of the black-white box (n = 8-10/group). Rats were videotaped and the tapes were scored for latency to exit the white chamber, latency to reenter the white chamber, time spent in the white chamber, intercompartmental crossing, and locomotor activity. ANOVA revealed no effect of the D1 antagonist SCH23390 on any behavioral measure. However, the raclopride-treated rats left the white area sooner than control rats (p < 0.01). Raclopride-treated rats also exhibited delayed reentry times to the white chamber compared to control rats (p < 0.01) and spent significantly less time in the white chamber (p < 0.05). Neither SCH23390 nor raclopride affected locomotor activity in a manner that confounded these behaviors. These results confirm that D2 receptor blockade enhances anxiety in rats tested in the black-white box.

Animals↗

PubMed1999

Intraaccumbens raclopride attenuates amphetamine-induced locomotion, but fails to prevent the response-reinstating properties of food reinforcement.

It has been well established that the presentation of a single reinforced trial in the midst of extinction results in a reinstatement of the previously reinforced operant response. In previous experiments, we have shown that systemically applied raclopride (a selective dopamine D2 receptor antagonist) dose dependently blocked the response-reinstating properties of food reinforcement, while SCH39166 (a selective dopamine D1 receptor antagonist) did not (11). The current experiments investigated the possible role of the nucleus accumbens in these actions of raclopride. In the first of two experiments, hungry rats were trained to traverse a straight runway for food reinforcement, a response that was then weakened through a series of extinction trials. On a single treatment trial, subjects were infused with one of three doses of intraaccumbens raclopride (0.0, 2.5, or 5.0 microg/0.5 microl/side) just prior to a reinforced trial. Twenty-four hours later, a single test trial was run in an unbaited runway. The results demonstrate that the prior day's reinforced trial produced a reinstatement of operant runway performance that was unaltered by intraaccumbens applications of raclopride. Two days later, the same animals were tested in a second experiment investigating the effects of intraaccumbens raclopride on amphetamine-induced locomotion. Subjects were pretreated with 1.0 mg/kg s.c. amphetamine prior to a 90-min locomotor activity session. The following day, subjects were again pretreated with amphetamine, but this time with a challenge dose of raclopride. Results demonstrate that the same raclopride doses that produced no effect in the response-reinstating experiment produced, in the same rats, a dose-dependent attenuation in amphetamine-induced locomotion. These data suggest that dopamine D2 receptors in the nucleus accumbens may not, in and of themselves, be necessary for the response-reinstating effects of food reinforcement.

Amphetamine↗

PubMed1999

DA1 receptor activity opposes anorectic responses to amino acid-imbalanced diets.

The serotonin3 (5-HT3) receptor plays an important role in the aminoprivic feeding model. Other neurochemical systems, including cholecystokinin (CCK) and dopamine (DA), are known to affect food intake. We pretreated rats systemically with tropisetron, a 5-HT3 receptor antagonist, alone and combined with antagonists of DA1 and DA2 receptors, and measured intake of an amino acid-imbalanced diet (IMB). As expected, tropisetron significantly increased intake of IMB. SCH-23390, a DA1 antagonist, increased IMB anorexia. When combined with tropisetron, DA2 antagonism with eticlopride reduced short-term intake of both the basal diet (BAS) and IMB. In the IMB model, specificity of 5-HT3-DA2 interactions, and of 5-HT3-CCK(A) interactions from previous studies, prompted investigation of CCK(A)-DA2 interactions; there appeared to be none. SKF-38393, a DA1 agonist, combined with the CCK(A) receptor antagonist, devazepide, increased BAS and tended to increase IMB intake. Thus, CCK(A)-DA1 interactions were not specific for IMB. These data suggest that DA1 receptor activity opposes IMB anorexia, possibly via an interaction with the 5-HT3 receptor.

2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-ben↗

PubMed1999

The dopamine D3/D2 receptor agonist 7-OH-DPAT induces cognitive impairment in the marmoset.

Previous work has shown that dopaminergic systems are involved in cognitive function in the common marmoset. The present study investigated the role of dopamine D3 receptors in cognitive performance in the marmoset. The effects of the putative dopamine D3 receptor agonist, 7-OH-DPAT, on performance of a same-day reversal visual object discrimination task were assessed using a miniature Wisconsin General Test Apparatus (WGTA). Within the same test session marmosets acquired a two-choice object discrimination initial task and a reversal task to criterion. 7-OH-DPAT (6-10 microg/kg) significantly impaired reversal task performance only, without affecting acquisition of the initial task. A higher dose of 25 microg/kg 7-OH-DPAT impaired initial task acquisition as well as reversal task acquisition, possibly as a consequence of a nonspecific influence on motor function. The dopamine D2 receptor antagonist (-)sulpiride (5-10 microg/kg) and the alpha2-receptor antagonist yohimbine (50 microg/kg) failed to attenuate the effects of 7-OH-DPAT (6 microg/kg) in this task. In contrast, the dopamine D2/D3 receptor antagonist raclopride (50 microg/kg) significantly attenuated the 7-OH-DPAT-induced impairment of reversal task performance. These results suggest that activation of dopamine D3 receptors produces a selective impairment of aspects of cognitive function in the marmoset.

Adrenergic alpha-Antagonists↗

PubMed1999

Dopamine antagonists in the orbital prefrontal cortex reduce prepulse inhibition of the acoustic startle reflex in the rat.

Schizophrenia is characterized by, among other things, (a) information processing deficits that have been indexed by a number of measures, including deficits in prepulse inhibition (PPI) of the acoustic startle reflex; and (b) pathophysiology of the frontal lobe. Recent studies have implicated the prefrontal cortex (PFC) in the modulation of PPI in rats. These studies suggest that dopamine (DA) ablation of the PFC (using 6-OHDA) leads to disruption of PPI. To better understand the role of DA type 1 (D1) and type 2 (D2) receptors in the modulation of PPI, we investigated the effects of two pharmacologically distinct DA antagonists on the modulation of PPI. Microinjection of SCH23390 (a D1 antagonist) into the orbital PFC markedly decreased PPI (at 0.1, 0.5, and 1.5 microg), whereas raclopride (a D2 antagonist) decreased PPI at some doses (0.1 and 0.5 mg/ml) but not at others (5.0 microg). We conclude that both D1 and D2 receptors mediate the cortical modulation of PPI.

Acoustic Stimulation↗

PubMed1999

Lead-induced decrements in waiting behavior: involvement of D2-like dopamine receptors.

Some behavioral changes produced by chronic postweaning lead (Pb) exposure have been linked to mesolimbic dopamine (DA) system alterations. This study sought to determine the role of DA systems in Pb-induced changes in a fixed ratio (FR) waiting-for-reward paradigm. Rats exposed chronically from weaning to 0, 50, or 150 ppm Pb acetate drinking solutions earned free reinforcers for waiting after completion of an FR, with increasing time between successive free reinforcers. Responses during the waiting period reset the FR requirement. Once performance stabilized, the effects of acute IP administration of the D1 agonist SKF82958, the D2 agonist quinpirole, the D1 antagonist SCH23390, and the D2 antagonist eticlopride were determined. Pb itself increased FR response rates and decreased mean waiting time, a pattern of behavior that increased the number of earned reinforcers, but doubled the number of responses/reinforcer. None of the DA compounds mimicked Pb effects when administered to controls. Only DA agonists altered waiting behavior and responses per reinforcer. Quinpirole, in particular, appeared to reverse Pb effects on the FR wait baseline by increasing waiting time and decreasing FR resets to control levels. These findings point to a particular role for D2 DA function in Pb's detrimental effects on waiting.

Animals↗

PubMed1999

Effects of SCH 23390, raclopride, and haloperidol on morphine withdrawal-induced aggression in male mice.

Dopamine seems to play a very important role in aggressive behavior observed in morphine withdrawal. The effect of SCH 23390 (0.5 mg/kg), raclopride (0.3 mg/kg), and haloperidol (0.1 mg/kg) on morphine withdrawal-induced aggression has been studied in this work. Mice were rendered dependent by a daily injection of morphine (2.5 mg/kg) for 14 days. Three different experiments were carried out with the objective to evaluate the antiaggressive effect of the dopamine antagonists on: first, spontaneous morphine withdrawal; second, naloxone-induced withdrawal; and third, naloxone-induced withdrawal after previous administration of the neuroleptics. Thirty minutes after injection of the dopamine antagonists, experimental animals were confronted in a neutral area with anosmic, group-housed conspecifics (standard opponents), and aggression was evaluated by estimation of times allocated to 11 different behavioral categories. Morphine withdrawal produced an increase in aggressive behavior and a decrease in social and nonsocial behaviors. The three neuroleptics counteracted this aggression, but when SCH 23390 (selective D1 antagonist) and haloperidol (mixed D1/D2 antagonist) were administered in naloxone-induced withdrawal, the effect was greater in comparison to the spontaneous withdrawal. However, no changes were observed after raclopride administration (selective D2 antagonist). In conclusion, the alterations in the dopaminergic system produced by opiate withdrawal depend on the type of withdrawal produced, and this produces a change in the antiaggressive potency of the dopamine antagonists.

Aggression↗